Trending...
- Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
- Tacoma: Applicants Sought for the Equity in Contracting Advisory Committee
- "Rehabilitative Prison Program Compromised by Alleged Staff Misconduct, Whistleblower Claims"
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
Related Market Intelligence Reports:
More on Washingtoner
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
- Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
- Unlocking Multi-Sector Growth; Graphite Acquisition Powers EV Entry While Streamlined Consumer Snack Business Fuels Growth: (N A S D A Q: SOWG)
- Permian Museum Adds Carbonaceous Chondrite Reference Photos
- L2 Aviation Receives FAA STC and PMA for Klatt Works SAVED™ Smoke Vision System
- Axencis Launches Performance Partnership for Brand Protection
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
- Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
- Urge Incontinence
- Stress Incontinence
- Over-flow Incontinence
- Mixed Incontinence
- Other Type
- Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
- Anticholinergic/Antispasmodic Agents
- Skeletal Muscle Relaxants
- Antidepressants
- Alpha Blockers
- Topical Estrogens
- Others
- Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Urinary Incontinence Treatment Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
More on Washingtoner
- CCHR Says New OIG Report Raises Concerns about Drugging Elderly with Antipsychotics
- Spokane: Abor Day Celebration 2026
- Spokane Launches 'Summer of Soccer' Community Campaign
- Project Pretzel Introduces a New System for Running Renovation Projects with Built In Contracts and Real Time Execution
- Holistic Animal Wellness Expert Vicki Draper Releases Ebook to Help Pet Parents Reduce Anxiety and Create Calm Homes
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- Whiteside & Goldberg Investigating Claims on Behalf of Victims in TJ Maxx Hidden Camera Incident in Machesney Park, Illinois
- "Fearless and Free": Long Beach Pride 2026 Celebrates Resilience, Family, and Multicultural Connection
- 50 Years of Small Business Wisdom, Supercharged by AI: Shelly Berman Launches The Business Health Check
- Deborah E. Jones Releases Emotional Sovereignty, a Book on Emotional Awareness and Self-Regulation
- Finding the Best Lawyer: What Really Matters When Your Case Is on the Line
- The New World of Freight Brokering with AI
- Captain Notepad Launches Full-Service Direct Mail Platform for Small Businesses Nationwide
- World Cup Buzz Fuels Nayarit's Rise as Mexico's Pacific Standout
- Nayarit strengthens its position in Mexico's Culinary Elite with 8 restaurants in the 2026 Mexico Gastronomic Guide
- Winter Garden Ski Lake Home Sells for $2.05M in Cash Transaction, Highlighting Demand for Strategically Positioned Luxury Properties
- Strobert Tree Services' "50 Shades of Green" Campaign Encourages Arbor Day Action Across Delaware and Pennsylvania
- As Fluoride Debate Grips the Nation, Americans Turn to Whole-House Fluoride Filters for Answers
- FOCUS Hires Carrier-Side Operations Leader to Build the Next Generation of Insurance Service Delivery
- Adams Security Group LLC Launches New Website to Expand Professional Security Services Across Florida
- Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
- Peernovation And Inception Stratos Launch Joint Venture To Build A Global Peer-powered Performance Platform
- GDE Tree Services Expands Operations Across Logan, Ipswich and the Gold Coast
- UK AltNet FullFibre Solves IPv4 Shortage With netElastic BNG And CGNAT Networking Software
- Tacoma: Applicants Sought for the Equity in Contracting Advisory Committee
- Tacoma: Hylebos Bridge Closed to Vehicular Traffic